Last reviewed · How we verify

Human African trypanosomiasis (HAT) due to Trypanosoma brucei gambiense — Treatment Landscape & Competitive Intelligence

Human African trypanosomiasis (HAT) due to Trypanosoma brucei gambiense (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Human African trypanosomiasis (HAT) due to Trypanosoma brucei gambiense, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Fexinidazole FEXINIDAZOLE Sanofi Nitroimidazole Antimicrobial [EPC] 2021-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Sanofi · 1 drug in Human African trypanosomiasis (HAT) due to Trypanosoma brucei gambiense

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Human African trypanosomiasis (HAT) due to Trypanosoma brucei gambiense:

Cite this brief

Drug Landscape (2026). Human African trypanosomiasis (HAT) due to Trypanosoma brucei gambiense — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/human-african-trypanosomiasis-hat-due-to-trypanosoma-brucei-gambiense. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing